Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Insomnia is a significant public health burden, increasing work absenteeism and health care
costs in a large proportion of the population. It causes altered cognition, emotional
disturbances, and reduced quality of life. The purpose of this study is to determine whether
the sleep promoting effect of dexmedetomidine is superior to the conventional sleep promoting
drug, zolpidem.
The main outcome of this study is to measure the time taken to fall asleep. Investigators
will also look at incidences of wakening after sleep onset, sleep quality and wake time
during sleep.